BCL2 and acute myeloid leukemia: Venetoclax is a potent and selective inhibitor of BCL-2 and was approved in 2018 by the FDA and later by EMA in combination with either DNA methyltransferase inhibitors (DNMTi’s) or low-dose cytarabine (LDAC) in older or unfit AML patients [115,116].